Claims

Search Type State Status Topic Model Order Counting Over

As of snapshot 27745 under ledger-default@0.3.0.

Claim	Type	Assessment	Score	Review checks	References
In the same phase 1b/2 study, the regimen produced a 95% disease-control rate among the 40 analyzed participants.	QUANTITATIVE	Supported	0.9781	1 of 4	120
In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55% objective response rate.	QUANTITATIVE	Supported	0.9938	1 of 4	132